fda warning on compounded semaglutide alerts health care providers, compounders and patients of dosing errors associated with injectable products FDA Warns Against Compounded Semaglutide

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide and costs to consumers will triple, from $350 a month to $1,000.

Wegovy users report an average weight loss of 15-22% of body weight in clinical trials, with some patients losing more than 50 pounds

GLP-1 agonists are a class of drugs with a growing reputation for their role in weight management

Medicare is already spending billions on drugs like Ozempic, and Biden recently proposed expanding access to obesity treatments.

We're well-known as one of the leading Retatrutide peptide manufacturers and suppliers in China

Nausea and GI upset